<DOC>
	<DOCNO>NCT00343226</DOCNO>
	<brief_summary>The objective study : To compare renal function quadruple immunosuppressive regimen ( include basiliximab combination optimize cyclosporine dose first week post-transplantation , mycophenolate mofetil corticosteroid ) versus standard triple therapy regimen ( include cyclosporine standard dose , mycophenolate mofetil corticosteroid )</brief_summary>
	<brief_title>An Open , Randomized Pilot Study Evaluate Use Basiliximab With Optimized Cyclosporine Dosing Renal Function `` de Novo '' Liver Transplantation .</brief_title>
	<detailed_description />
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria First cadaveric liver transplant ABO identical compatible graft Exclusion Criteria Multiple organ transplant renal impairment define glomerular filtration rate ( GFR ) &lt; 30 ml/min Fulminant liver failure Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Basiliximab , transplantation , liver , renal function</keyword>
</DOC>